Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 4;12:790990. doi: 10.3389/fgene.2021.790990

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 You, Yang, Yan, Wang, Huang, Wang, Gao, Li and Lian.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Metabolomics profiling of plasma from SAA patients and healthy donors. (A) PLS-DA plot showing the metabolic profiles of the SAA (pink dots, n = 14) and HD (green dots, n = 15) groups. (B) The variable importance in projection (VIP) score plot showing the top 15 PLS-DA metabolites that are different between SAA patients and HD. (C) Volcano plot showing differential metabolites (fold change >2, p < 0.05) between SAA patients and HD analyzed by MetaboAnalyst website. The upregulated metabolites are enriched with drug and hormone-related metabolites. (D) MSEA plot showing enriched pathways of upregulated (fold change >2) and downregulated (fold change <2) metabolites in the SAA group. (E) PLS-DA plot showing metabolic profiles of the BM supernatant (pink dots, n = 5) and plasma (green dots, n = 14) in SAA patients. (F) VIP score plot showing the top 15 PLS-DA metabolites that are different between BM supernatant and plasma. (G) Volcano plot showing differential metabolites (fold change >2, p < 0.05) between BM supernatant and plasma analyzed by MetaboAnalyst website. (H) MSEA plot showing enriched pathways of upregulated (fold change >2) and downregulated (fold change <2) metabolites in BM supernatant of SAA patients. SAA, severe aplastic anemia; PLS-DA, partial least squares discriminant analysis; HD, healthy donors; MSEA, metabolite set enrichment analysis; BM, bone marrow.